Transthyretin Protects against A-Beta Peptide Toxicity
Author Information
Author(s): Costa Rita, Ferreira-da-Silva Frederico, Saraiva Maria J., Cardoso Isabel
Primary Institution: Instituto de Biologia Molecular e Celular, Porto, Portugal
Hypothesis
Can transthyretin (TTR) cleave A-Beta peptide and protect against its toxicity?
Conclusion
TTR cleaves A-Beta peptide, reducing its amyloidogenic potential and toxicity, suggesting a protective role in Alzheimer's disease.
Supporting Evidence
- TTR was shown to cleave A-Beta at multiple sites, resulting in smaller, less toxic peptides.
- Experiments demonstrated that TTR inhibits A-Beta aggregation and reduces its toxicity.
- TTR's protective effect was confirmed in cell culture and animal models.
- The presence of Kunitz Protease Inhibitor (KPI) peptides inhibited TTR's ability to cleave A-Beta.
Takeaway
Transthyretin helps protect the brain from a harmful protein called A-Beta by cutting it into smaller pieces that are less dangerous.
Methodology
The study involved incubating A-Beta peptides with TTR and analyzing the cleavage products using mass spectrometry and other biochemical assays.
Limitations
The study does not address the long-term effects of TTR on A-Beta clearance in vivo.
Statistical Information
P-Value
p<0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website